Key result
IRAP inhibition prevents age-related GFR decline and attenuates renal fibrosis and senescence in mice.
Why the study?
To determine whether the angiotensin IV/insulin-regulated aminopeptidase (IRAP) axis of the renin-angiotensin system contributes to renal function decline, fibrosis, and senescent cell accumulation in aged mice.
Does IRAP inhibition prevent age-related decline in renal function and cellular senescence in aged mice?
Does IRAP inhibition prevent age-related decline in renal function and cellular senescence in aged mice?
IRAP inhibition represents a potential therapeutic strategy to attenuate pathological cardiorenal aging through senoprotective mechanisms.
IRAP inhibition may attenuate renal senescence in aged mice; leaves open translation to human kidney aging or clinical use.
Senescent cell accumulation and fibrosis play a fundamental role in kidney ageing. Our aim was to determine whether the angiotensin IV/insulin-regulated aminopeptidase (IRAP) axis of the renin-angiotensin system contributes to renal function decline, fibrosis and senescent cell accumulation in aged mice. We studied the role of IRAP in kidney aging using IRAP knockout mice, as well as in wildtype mice treated with an IRAP inhibitor. Complementary proximal tubule and collecting duct cell models were used to determine the mechanisms by which IRAP inhibition exerts protective effects. Glomerular filtration rate declined by 25% in wild-type mice between 3-23 months of age, concomitant with marked increases in albumin excretion, glomerulosclerosis, tubulointerstitial fibrosis and accumulation of senescent cells in the proximal tubules of the kidney. IRAP knockout mice were protected against age-related decline in glomerular filtration rate, renal fibrosis and senescence burden compared to age-matched wildtype mice. IRAP inhibition for 4 weeks (HFI-419, 500 ng/kg/min) in 28-month-old wild-type mice similarly prevented age-related decline in glomerular filtration rate and attenuated expression of cellular senescence markers. Using an in vitro model of cultured proximal tubule cells, IRAP inhibition mitigated the pro-senescent effects of oxidative stress. This was associated with shifts in the metabolic phenotype of proximal tubular cells, indicating senoprotective effects of IRAP inhibition may be mediated in part via mitochondrial function. These studies provide evidence that IRAP deficiency is protective against chronic renal cellular senescence, fibrosis and functional decline. Therefore, IRAP inhibition has therapeutic potential to attenuate pathological cardiorenal ageing through senoprotective mechanisms.
No takes yet. Share an insight, caveat, or question.
Walton et al. (2026) studied Kidney aging and renal cellular senescence. IRAP deficiency or IRAP inhibition (HFI-419) vs. Wild-type mice or vehicle treatment was evaluated on Glomerular filtration rate (GFR) decline and cellular senescence markers. IRAP deficiency or pharmacological inhibition with HFI-419 prevented age-related decline in glomerular filtration rate and attenuated renal fibrosis and cellular senescence in aged mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: